NASDAQ:AXGN AxoGen (AXGN) Stock Price, News & Analysis $13.95 -0.05 (-0.36%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About AxoGen Stock (NASDAQ:AXGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AxoGen alerts:Sign Up Key Stats Today's Range$13.89▼$14.2450-Day Range$12.65▼$14.7152-Week Range$3.56▼$15.23Volume259,545 shsAverage Volume397,170 shsMarket Capitalization$611.43 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingBuy Company OverviewAxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Read More… Crypto Crash Ahead? (27 Experts Weigh In) (Ad)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. AxoGen Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks21st Percentile Overall ScoreAXGN MarketRank™: AxoGen scored higher than 21% of companies evaluated by MarketBeat, and ranked 889th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingAxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAxoGen has only been the subject of 1 research reports in the past 90 days.Read more about AxoGen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.33) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -36.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -36.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 6.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AxoGen's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.81% of the outstanding shares of AxoGen have been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AxoGen has recently increased by 1.65%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.81% of the outstanding shares of AxoGen have been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AxoGen has recently increased by 1.65%, indicating that investor sentiment is decreasing. News and Social Media2.0 / 5News Sentiment0.56 News SentimentAxoGen has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for AxoGen this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added AxoGen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.00% of the stock of AxoGen is held by insiders.Percentage Held by Institutions80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AxoGen's insider trading history. Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address AXGN Stock News HeadlinesAxogen Inc (AXGN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...October 9, 2024 | finance.yahoo.comAxogen, Inc. (NASDAQ:AXGN) is a favorite amongst institutional investors who own 63%October 8, 2024 | finance.yahoo.comNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. November 2, 2024 | Porter & Company (Ad)Axogen (NASDAQ:AXGN) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comZacks.com featured highlights include Bioventus, Great Lakes Dredge & Dock and AxoGenSeptember 24, 2024 | finance.yahoo.comAxoGen: An Intriguing Growth StorySeptember 17, 2024 | seekingalpha.comArrowMark Colorado Holdings LLC Reduces Stake in Axogen IncSeptember 12, 2024 | finance.yahoo.comAxoGen, Inc. (NASDAQ:AXGN): Are Analysts Optimistic?September 11, 2024 | finance.yahoo.comSee More Headlines AXGN Stock Analysis - Frequently Asked Questions How have AXGN shares performed this year? AxoGen's stock was trading at $6.83 at the beginning of 2024. Since then, AXGN shares have increased by 104.2% and is now trading at $13.95. View the best growth stocks for 2024 here. How were AxoGen's earnings last quarter? AxoGen, Inc. (NASDAQ:AXGN) announced its quarterly earnings results on Thursday, August, 8th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.10. The medical equipment provider had revenue of $47.91 million for the quarter, compared to analysts' expectations of $43.27 million. AxoGen had a negative trailing twelve-month return on equity of 17.30% and a negative net margin of 9.53%. Who are AxoGen's major shareholders? Top institutional investors of AxoGen include Perkins Capital Management Inc. (0.65%), Rice Hall James & Associates LLC (0.44%), Exchange Traded Concepts LLC (0.17%) and Semanteon Capital Management LP (0.10%). Insiders that own company stock include Karen L Zaderej, Gregory Gene Freitag, Erick Wayne Devinney, Amy Mcbride Wendell, Guido J Neels, Peter J Mariani, Michael Patrick Donovan and William P Mr Burke. View institutional ownership trends. How do I buy shares of AxoGen? Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that AxoGen investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings8/08/2024Today11/02/2024Next Earnings (Confirmed)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:AXGN CUSIPN/A CIK805928 Webwww.axogeninc.com Phone(386) 462-6800Fax386-462-6801Employees426Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$20.00 Low Stock Price Target$12.00 Potential Upside/Downside+7.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,720,000.00 Net Margins-9.53% Pretax Margin-9.53% Return on Equity-17.30% Return on Assets-8.63% Debt Debt-to-Equity Ratio0.70 Current Ratio3.51 Quick Ratio2.32 Sales & Book Value Annual Sales$159.01 million Price / Sales3.85 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book6.28Miscellaneous Outstanding Shares43,830,000Free Float40,762,000Market Cap$611.43 million OptionableOptionable Beta1.13 Social Links 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:AXGN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AxoGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.